Evidence map›Paper›PMID 32013978›Full record

Trial reportWorld journal of surgical oncology2020

Short-term outcomes of laparoscopic intersphincteric resection with intraoperative radiotherapy using low-energy X-rays for primary locally advanced low rectal cancer: a single center experience.

Wangsheng Xue, Shuang Wang, Zeyun Zhao, Yongbo Li, An Shang, Donglin Li, Jianzheng Yang, Tiejun Wang, Min Wang

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Latest Advances in Intersphincteric Resection for Low Rectal Cancer.Gastroenterology research and practice · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Wangsheng XueDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Shuang WangDepartment of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Zeyun ZhaoDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Yongbo LiDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
An ShangDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Donglin LiDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Jianzheng YangDepartment of Radiology, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Tiejun WangDepartment of Radiology, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Min WangDepartment of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China. jdeywangmin@163.com.ORCID http://orcid.org/0000-0002-1288-016X
Second Affiliated Hospital of Jilin University · CN

Funding

Jilin Scientific and Technological Development Program (CN) grant no. 20170204042SF
6 · The paper itself

Abstract

backgroundEven with the augmentative application of anal-preservation surgery in low rectal cancer, the role and indications of laparoscopic intersphincteric resection (Lap ISR) are still under debate, especially for T3 or node-positive (T3N0M0, T1-3N+M0) cancer, mainly due to the oncological safety and functional outcomes. INTRABEAM (Carl Zeiss, Germany) intraoperative radiotherapy (IORT) using low-energy X-rays features in accurate irradiation, less exposure, and reduced complications. Taking advantages of Lap ISR and INTRABEAM IORT, this innovative approach aims to increase the probability of the anal preservation with acceptable postoperative outcomes. MATERIALS AND

methodsFrom December 2015 to August 2019, we retrospectively analyzed the short-term outcomes of 12 patients evaluated preoperatively with T3 or node-positive (T3N0M0, T1-3N+M0) primary locally advanced low rectal cancer. They all had received Lap ISR and INTRABEAM IORT with a dose of 16-18 Gy applied by an applicator through the anus (natural orifice). Then, with no pre- or postoperative radiotherapy given, the patients were suggested to receive 6-8 cycles of the XELOX chemotherapy regimen (oxaliplatin, 130 mg/m

resultsAll patients achieved R0 resection. The median radiation time was 27 min and 15 s, and the mean radiative dose was 17.3 Gy (range 16-18 Gy). The median follow-up time was 18.5 months (range 3-45 months). Two patients experienced local recurrence. Two male patients experienced anastomotic stenosis. Furthermore, one of them experienced perianal abscess and the other one experienced pulmonary metastasis after refusing to receive chemotherapy. One female patient with internal anal sphincter invasion experienced distant metastases to the liver and gluteus maximus muscle 35 months after IORT. No acute radiation injuries or symptoms were observed. Although they experienced a reduction in anal function, every patient was satisfied with the postoperative outcomes.

conclusionsFor patients evaluated preoperatively with T3 or node-positive (T3N0M0, T1-3N+M0) primary locally advanced low rectal cancer, Lap ISR with INTRABEAM IORT may be a safe and feasible approach for anal preservation without compromising oncological outcomes.

Indexed as

Intraoperative CareAgedAged, 80 and overAnal CanalAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDigestive System Surgical ProceduresFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedRadiotherapy, AdjuvantRadiotherapy DosageRectal NeoplasmsIORTLap ISRLow-energy X-raysLow rectal cancerT1–3N+M0T3N0M0

Identifiers

PMID32013978
PMCPMC6998155
OpenAlexW3007577881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.